XFRA CAPITAL ADJUSTMENT INFORMATION

XFRA CAPITAL ADJUSTMENT INFORMATION - 26.08.2025

Das Instrument 14B0 NO0013470534 HUDDLY AS NK -,0625 EQUITY wird ex Kapitalmassnahme gehandelt am 26.08.2025
The instrument 14B0 NO0013470534 HUDDLY AS NK -,0625 EQUITY is traded ex capital adjustment on 26.08.2025

Das Instrument OND SE0009414576 ONCOPEPTIDES AB O.N. EQUITY wird cum Kapitalmassnahme gehandelt am 26.08.2025 und ex Kapitalmassnahme am 27.08.2025
The instrument OND SE0009414576 ONCOPEPTIDES AB O.N. EQUITY is traded cum capital adjustment on 26.08.2025 and ex capital adjustment on 27.08.2025

Das Instrument 7QF NO0010921232 AKER HORIZONS ASA NK 0,01 EQUITY wird ex Kapitalmassnahme gehandelt am 26.08.2025
The instrument 7QF NO0010921232 AKER HORIZONS ASA NK 0,01 EQUITY is traded ex capital adjustment on 26.08.2025

Solarbranche vor dem Mega-Comeback?

Lange galten Solaraktien als Liebling der Börse, dann kam der herbe Absturz: Zinsschock, Überkapazitäten aus China und ein Preisverfall, der selbst Marktführer wie SMA Solar, Enphase Energy oder SolarEdge massiv unter Druck setzte. Viele Anleger haben der Branche längst den Rücken gekehrt.

Doch genau das könnte jetzt die Chance sein!
Die Kombination aus KI-Explosion und Energiewende bringt die Branche zurück ins Rampenlicht:

Rechenzentren verschlingen Megawatt – Solarstrom bietet den günstigsten Preis je Kilowattstunde
Moderne Module liefern Wirkungsgrade wie Atomkraftwerke
hina bremst Preisdumping & pusht massiv den Ausbau

Gleichzeitig locken viele Solar-Aktien mit historischen Tiefstständen und massiven Short-Quoten, ein perfekter Nährboden für Kursrebound und Squeeze-Rally.

In unserem exklusiven Gratis-Report zeigen wir dir, welche 4 Solar-Aktien besonders vom Comeback profitieren dürften und warum jetzt der perfekte Zeitpunkt für einen Einstieg sein könnte.

Laden Sie jetzt den Spezialreport kostenlos herunter, bevor die Erholung am Markt beginnt!

Dieses Angebot gilt nur für kurze Zeit – also nicht zögern, jetzt sichern!

Hier klicken

Zeit	Aktuelle Nachrichten
Do	Aker Horizons ASA: The merger between Aker Horizons Holding AS and AKH HoldCo AS is completed	FORNEBU, Norway, Sept. 11, 2025 /PRNewswire/ -- Reference is made to the previous announcements made by Aker Horizons ASA (the "Company" or "Aker Horizons") regarding the merger between its... ► Artikel lesen
Do	Aker ASA: The merger between Aker Horizons Holding AS and AKH HoldCo AS is completed	OSLO, Norway, Sept. 11, 2025 /PRNewswire/ -- Reference is made to the previous announcements made by Aker ASA (the "Company" or "Aker") regarding the merger between its indirect subsidiary... ► Artikel lesen
05.09.	Aker Horizons ASA: Ex. dividend in-kind today	FORNEBU, Norway, Sept. 5, 2025 /PRNewswire/ -- Issuer name: Aker Horizons ASA (the "Company") Ex. Date: 5 September 2025 Type of corporate action: Distribution of shares in... ► Artikel lesen
05.09.	XFRA CAPITAL ADJUSTMENT INFORMATION - 05.09.2025	Das Instrument 7QF NO0010921232 AKER HORIZONS ASA NK 0,01 EQUITY wird ex Kapitalmassnahme gehandelt am 05.09.2025 The instrument 7QF NO0010921232 AKER HORIZONS ASA NK 0,01 EQUITY is traded ex capital... ► Artikel lesen
01.09.	Aker Horizons ASA: Mandatory notification of trade	FORNEBU, Norway, Sept. 1, 2025 /PRNewswire/ -- Reference is made to the announcements made today by Aker Horizons ASA (the "Company") regarding the satisfaction of the conditions for the... ► Artikel lesen

Zeit

Aktuelle Nachrichten

Aker Horizons ASA: The merger between Aker Horizons Holding AS and AKH HoldCo AS is completed

FORNEBU, Norway, Sept. 11, 2025 /PRNewswire/ -- Reference is made to the previous announcements made by Aker Horizons ASA (the "Company" or "Aker Horizons") regarding the merger between its...
► Artikel lesen

Aker ASA: The merger between Aker Horizons Holding AS and AKH HoldCo AS is completed

OSLO, Norway, Sept. 11, 2025 /PRNewswire/ -- Reference is made to the previous announcements made by Aker ASA (the "Company" or "Aker") regarding the merger between its indirect subsidiary...
► Artikel lesen

05.09.

Aker Horizons ASA: Ex. dividend in-kind today

FORNEBU, Norway, Sept. 5, 2025 /PRNewswire/ -- Issuer name: Aker Horizons ASA (the "Company") Ex. Date: 5 September 2025 Type of corporate action: Distribution of shares in...
► Artikel lesen

05.09.

XFRA CAPITAL ADJUSTMENT INFORMATION - 05.09.2025

Das Instrument 7QF NO0010921232 AKER HORIZONS ASA NK 0,01 EQUITY wird ex Kapitalmassnahme gehandelt am 05.09.2025 The instrument 7QF NO0010921232 AKER HORIZONS ASA NK 0,01 EQUITY is traded ex capital...
► Artikel lesen

01.09.

Aker Horizons ASA: Mandatory notification of trade

FORNEBU, Norway, Sept. 1, 2025 /PRNewswire/ -- Reference is made to the announcements made today by Aker Horizons ASA (the "Company") regarding the satisfaction of the conditions for the...
► Artikel lesen

Zeit	Aktuelle Nachrichten
Do	Huddly AS: BT Group installs Huddly C1 at new Manchester office
09.09.	Huddly AS - Board resolution to increase share capital and mandatory notification of trade
09.09.	Huddly AS - Registration of share capital increase following the Private Placement
08.09.	Huddly AS - Mandatory notification of trade
08.09.	Huddly AS - Minutes from Extraordinary General Meeting

Zeit

Aktuelle Nachrichten

Huddly AS: BT Group installs Huddly C1 at new Manchester office

09.09.

Huddly AS - Board resolution to increase share capital and mandatory notification of trade

09.09.

Huddly AS - Registration of share capital increase following the Private Placement

08.09.

Huddly AS - Mandatory notification of trade

08.09.

Huddly AS - Minutes from Extraordinary General Meeting

Zeit	Aktuelle Nachrichten
28.08.	Oncopeptides AB: Oncopeptides publishes disclosure document regarding rights issue	THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, HONG KONG, ISRAEL, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SWITZERLAND... ► Artikel lesen
27.08.	Oncopeptides - Targeted oncology with commercial momentum	Oncopeptides (ONCO) is a Swedish biotech that aims to develop and commercialise therapies for difficult-to-treat cancers, with a focus on haematological diseases. Its lead product, Pepaxti, was approved... ► Artikel lesen
26.08.	XFRA CAPITAL ADJUSTMENT INFORMATION - 26.08.2025	Das Instrument 14B0 NO0013470534 HUDDLY AS NK -,0625 EQUITY wird ex Kapitalmassnahme gehandelt am 26.08.2025 The instrument 14B0 NO0013470534 HUDDLY AS NK -,0625 EQUITY is traded ex capital adjustment... ► Artikel lesen
25.08.	Oncopeptides AB: Oncopeptides enters into additional guarantee commitments, rights issue fully guaranteed	THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, HONG KONG, ISRAEL, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SWITZERLAND... ► Artikel lesen
21.08.	Oncopeptides Q2 2025 slides: 135% sales growth overshadowed by rights issue announcement

Zeit

Aktuelle Nachrichten

28.08.

Oncopeptides AB: Oncopeptides publishes disclosure document regarding rights issue

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, HONG KONG, ISRAEL, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SWITZERLAND...
► Artikel lesen

27.08.

Oncopeptides - Targeted oncology with commercial momentum

Oncopeptides (ONCO) is a Swedish biotech that aims to develop and commercialise therapies for difficult-to-treat cancers, with a focus on haematological diseases. Its lead product, Pepaxti, was approved...
► Artikel lesen

26.08.

XFRA CAPITAL ADJUSTMENT INFORMATION - 26.08.2025

25.08.

Oncopeptides AB: Oncopeptides enters into additional guarantee commitments, rights issue fully guaranteed

21.08.

Oncopeptides Q2 2025 slides: 135% sales growth overshadowed by rights issue announcement